Broken RECORD: New Themes, Same Old Story for Avandia
Executive Summary
Count Rep. Rosa DeLauro among those who remain highly critical of the Food and Drug Administration's handling of GlaxoSmithKline's type 2 diabetes drug Avandia (rosiglitazone). The Connecticut Democrat, whose chairmanship of the House Agriculture Appropriations Subcommittee gives her something like life-and-death authority over FDA, made her feelings on the subject abundantly clear during an Institute of Medicine workshop on regulatory science February 26
You may also be interested in...
Avandia Advisory Cmte. Is FDA's Primary Response To Congressional Pressure
Sponsors will get another look in July at how FDA interprets guidance for assessing the cardiovascular risk of diabetes drugs in clinical trials. The venue will be a meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials